Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 10

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 10
---
 effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.

We have included more detailed descriptions of these risks and uncertainties and other risks and uncertainties applicable to our business that
we believe could cause actual results to differ materially from any forward-looking statement in the “Risk Factors” sections of this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein
including, but not limited to, the risk factors incorporated by reference from our filings with the SEC. We encourage you to read those descriptions carefully. Although we believe we have been prudent in our plans and assumptions, no assurance can
be given that any goal or plan set forth in forward-looking statements can be achieved. We caution investors not to place significant reliance on forward-looking statements; such statements need to be evaluated in light of all the information
contained and incorporated by reference in this prospectus supplement and the accompanying prospectus. Furthermore, the statements speak only as of the date of each document, and we undertake no obligation to update or revise these statements.

S-6

USE OF PROCEEDS

We intend to use the net proceeds from this offering, if any, for working capital and other general corporate purposes which may include,
without limitation, research and development expenditures, preclinical and clinical development and commercialization of our product candidates, the acquisition or in-licensing of products or product
candidates, business or technologies, collaborations, working capital and capital expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over
the allocation of net proceeds.

S-7

DILUTION If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the public offering price per share and the as-adjustednet tangible book value per share after this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares of our common stock. As of March 31, 2025, we had a net tangible book value of $(21.8) million, or $(5.50) per share of common stock. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at March 31, 2025, after giving effect to the assumptions set forth below. After giving effect to